Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Revenues
Royalty and licensing revenue	$ 1,649	$ 0
Treatment investment revenue	54	11
Total revenue	1,703	11
Operating expenses
General and administrative	2,965	1,858
Research and development	2,421	890
License fees	5,625	0
Selling expenses	0	84
Total operating expenses	11,011	2,832
Loss from operations	(9,308)	(2,821)
Other income (expense)
Interest income	5	9
Gain (loss) on foreign exchange	(8)	15
Total other income (expense)	(3)	24
Loss before provision for income taxes	(9,311)	(2,797)
Provision for income taxes	33	0
Net loss	$ (9,344)	$ (2,797)
Loss per share of common stock
Basic and diluted (in dollars per share)	$ (3.68)	$ (1.39)
Weighted average common stock outstanding
Basic and diluted (in shares)	2,542,084	2,009,887